PTO/SB/08A (08-03) Approved for use through 07/31/2006, OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to re	U.S. Patent and Traden spond to a collection of informat	nark Office; U.S. DEPARTMENT OF COMM ion unless it contains a valid OMB control nu	ERCE umber
Substitute for form 1449/PTO	Complete if Known		
Substitute for form 1440/110	Application Number	10/599,143	
INFORMATION DISCLOSURE	Filing Date	April 1, 2005	
	First Named Inventor	Lain-Yen Hu	
STATEMENT BY APPLICANT	Art Unit		
(Use as many sheets as necessary)	Examiner Name		
 Chart 1 of 5	Attorney Docket Number	PC32134A	_

				T DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (F known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
		us- <sub>4263223</sub>	04-21-1981	Marc Pauly	1
		US-			
	1	US-			
		US-			
	<u> </u>	US-			
	<u> </u>	US-			
	_	US-			
		US-			
	$\vdash$	US-			
		US-			
		US-			
	1	US-			
	1	119.			

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages			
illiaio		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (# known)	MM-DD-YYYY		Or Relevant Figures Appear	Te		
		WO03/093243A1	11-13-2003	Aventis Pharma				
		WO2006/024942A1	03-09-2006	Warner-Lambert Co LLC				
		WO2006/006065A1	01-19-2006	Warner-Lambert Co LLC				
		WO2005/102990A1	11-03-2005	Warner-Lambert Co LLC				
		WO2006/049952A1	05-11-2006	Eli Lilly and Co.				
		WO02/085860A1	10-31-2002	Pfizer Limited				

Examiner	Date	
Signature	Considered	

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. "Applicant's unique citation designation number (optional). "See Krida Codes of USPTO Planter Documents at <u>investageology</u> or MPEP 901.04. "Enter Citition that issued the document, by the box-fiet rode (WPO Standard ST.3.) For Japanese patient documents, the indication of the year of the reign of the Emperor must proceed the serial number of the patient document. "Kind of document by the appropriate symbols as indicated on the document under WPO Standard ST.6 if possible." "Applicant is to place a other wints there if English language of the patient of the patient of the patient of the propriate symbols as indicated on the document under WPO Standard ST.6 if possible." "Applicant is to place a other wints the or if English language of the patient of t Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, USH I/U process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 UFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application from the USPTO. Three will vary depending upon the Individual growth of the Section of the amount of time you require to complete this form and/or suppressions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Chief and the Chief Ch

PTO/SB/08A (08-03) Approved for use through 07/31/2006, OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to Substitute for form 1449/PTO	o respond to a collection of informa	mark Office; U.S. DEPARTMENT OF Co ation unless it contains a valid OMB contr mplete if Known	
Substitute for form 1449/PTO	Application Number	10/599,143	
INFORMATION DISCLOSURE	Filing Date	April 1, 2005	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Lain-Yen Hu	
	Art Unit		
(Use as many sheets as necessary)	Examiner Name		
2 1 5	Attorney Docket Number	DC32131A	

Examiner	Oit-	Document Number	U. S. PATENT D Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	Cite No.1		MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2 (F known)</sup>			Figures Appeal
		US-			1
		US-			4 1
		US-			
	-	US-			
	<del>                                     </del>	US-			
	-	US-	-		+

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages				
milaio		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (if known)  MM-DD-YYYY			Or Relevant Figures Appear	T			
		WO2005/108361A1	11-17-2005	Janssen Pharmaceutica					
		EP0684235A1	11-29-1995	Mochida Pharm. Co.					
		EP0601977A1	06-15-1994	CIBA-GEIGY AG					
		EP0080371A1	06-01-1983	Takeda Chem Ind.					
		DE2301541	09-06-1973	Miles Labs Inc					
		WO02/057215A2	07-25-2002	Advanced Medicine, Inc.					

Examiner	Date	
Signature	Considered	

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 605. Daw into through citation if not in conformance and net considered, include copy of the form with next communication to applicant. Applicant's unique citation designation number optimizes to get infance bodies. USPTO Present Documents at toxic applications of MPEP or infance bodies in Capital Conformation and Capital Capital Capital Capital Conformation and Capital Capital

This calculation of information is required by 37 CFR, 197 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Conditionality is governed by 38 US, 6, 122 and 37 CFR, 114. This collection is estimated to take 2 bourts complete, including gathering, preparing, and submitting the completed application form to the USPTO. Then will vary depending upon the individual case. Any comments on the amount of line you require to complete this form and/or suggestations for reducing this burden, should be sent to the Chief Information Clierce, U.S. Patent and Trademark Cffice, P.O. Sex 1450, Alexandria, VAX 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Sex 1450, Abstracting, W.Z. 2231-2450.

PTC/SB/08A (08-03) Approved for use through 07/31/2006. OMB 0651-0031

						nark Office; U.S. DEPARTMENT OF COMMERCE	
	Under	the Paperwork Reduction	Act of 1	995, no persons are required to re		tion unless it contains a valid OMB control number	
	Subs	titute for form 1449/PTO			Complete if Known		
					Application Number	10/599,143	
	INI	EODMATIO!	ום וא	SCLOSURE	Filing Date	April 1, 2005	
		. •			First Named Inventor	Lain-Yen Hu	
STATEMENT BY APPLICANT (Use as many sheets as necessary)					Art Unit		
					Examiner Name		
_	Oheart	2		5	Attorney Docket Number	PC32134A	

U. S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (* known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		US-			;		
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages			
IIIIIiiii	140.	Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	7 ppinoant of Ones Document	Or Relevant Figures Appear	T <sup>©</sup>		
		WO98/33779	08-06-1998	Dong Wha Pharm. Ind.				
		WO2004/018386A2	03-04-2004	Merck & Co., Inc.				
		WO03/074473A2	09-12-2003	University of Tennessee				
		WO2005/049574A1	06-02-2005	Warner-Lambert Co LLC				
		WO2005/100305A1	10-27-2005	Warner-Lambert Co LLC				

Examiner Signature	Date Considered	

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. "Applicant's unique citation designation number (epitonal). "See Knice Codes of USPTO Patent Documents at www.enispec.cog vm PeP 301-04." Either Color that issued the document, by the vol-tier code (VMPO Standard ST.3.)" For Apparence patient document, his indication of the year of the reign of the Emperor made procede the serial number of the patient document. "Kniff of document by the appropriate symbols as indicated on the document under VMPO Standard ST.6 if possible." "Applicant be to place a check mark the ref English binguage."

Internation is disconnected in sequence by 37 CPR, 197 and 1.98. The information is equipmed to obtain or retain a benefit by the public which is to file (and by the USPTO of promotion) an application. Confidentially is operanted by 38 U.S.C., 122 and 37 CPR, 114. This colloding in selfmand to lake 2 bourse to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Then well vary depending upon the individual case. Any comments on the amount of this you require to complete this form and/or suggestions for reducing this budges, should be sun to the Chief Information Officer, U.S. Patient and Trademark Office, P.D. Sen 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patients, P.O. Sox 1450, Naturalistic, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006, CMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
Substitute for form 144911 10				Application Number	10/599,143	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	Apri 1, 2005	
				First Named Inventor	Lain-Yen Hu	
				Art Unit		
(Use as many sheets as necessary)			ecessary)	Examiner Name		
Sheet	4	of	5	Attorney Docket Number	PC32134A	

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of				
Initials*	No.1					
		Database Capins Online Chemical Abstracts Service, Columbus, Obio US. BERG, S.S. ET.AL, "richamotherapeatic amidines X. Substituted 4,4-diamidine-omega, omega-diphenoxyallanes and diphenyl ethers XP002333841 retrieved from STIV Database accession no 1949:20548 abstract & Journal of the Chemical Society Abstracts, 1949, pages 642-648				
		Database Caplus Online Chemical Abstracts Service, Columbus, Otio US KRATZL, K. ET AL: "Chemistry of vanillin and its derivatives X. Amidines imidazolines, and tertahyd ropyrimidine dienes with quaiaced substituents" XP002333842 Retrieved from STN Database accession no. 1926-6268 abstract & Monatshiele Fuer Chemie, 88, 1957, pages 1056-1056.				
		Database Caplus Online Chemical Abstracts Service, Columbus, Ohio US DAVIS, M.: "Search for chomotherapeutic amidines, XV: 2-Methoxy and 2-hydroxy relavatives of 17-5-big-maintio-phenoxy patentes" N'20233847 retrieved from STN Database accession no. 1958;8:2447 abstract & Journal of the Chemical Society, Abstract, 1958, pages 907-908				
		DATA BASE CA Online Chemical Abstracts Service, Columbus, Ohio, US. FERRONI, R. Fa al., "Arromatic tetra- amidines: synthesis of habe-derivatives and their antiproteolytic activity" XP00233384 refrom TSTN Database accession to, 1926-91994 abstract & Farmano, Edition Scientifica, vol. 3p. no. 11, 1984, pages 501-509				
		DATA BASE CAPLUS Online Chemical Abstracts Service, Columbus, Onio 118 LEZNOFF, CLIFFORD C ET AL: "Metallophthulosynate dimens incorporating five-atom coverable tridges" NYPO233845 retrived from STN Database accession no. 1985;447150 abstract & Cumdain Journal of Chemistry VOI, 63, no. 3, 1985, pages 628-31				
		BAYTA JASE CAPILIS Cuting Chemical Abstracts Service, Columbus Colin US WOEBBLE, DISTER ET AL. "Hydrocire behalves comes and their pressures." Is Switteness of algebroise by Angles of the Common their pressures. It is writteness of algebroise pressure in phalves pressures and distribution expecting for against evivants in comprison to other phalacogramients. "SWID333846 retrieved from STN Distributes accession no. 1968-693724 abstract & MAKROMADELEGIAR CELEMBER 1818 for a 1988, page 1203-38.				
		GERATZ, J.D. ET AL: "Diamidino-alpha, omega-diphenocyallane s. Structure-activity relations for the inhibition of throuthin, panereatic kallikrein, and typsis" JOURNAL OF MEDICINAL CHEMISTRY, vol. 16, no. 9, 1973, pages 970-975, XP00233369 table VI. compounde 27-30, 22-34, 37				
		DATABASE CAPILIS Online CIEMICAL ABSTRACTS SERVICE, COLLABUS, OHIO US, CSOKAL, VICTOR ET AL: "Microwave-assisted synthesis of phalonitriles and phthalocyanines" XP002333847 retrieved from STN Database accession no. 2003;416216 abstract & STNTHETIC COMMUNICATIONS, vol. 33, no. 10, 2003, pages 1615-1621				
		DATABASE CAPLUS, Online CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US: EASTMOND, GIC. ET Alz. "Polymides with main-chain ethylene oxide units synthesis and properties" retrieved from STN Database accession no. 2002;264-646 abstract & POLYMER, vol. 43, no. 12, 2002. pages 345-53-668				
		DAT FANASE CAFALIS, Chinac CHEMICAL ABSTRACTS SERVICE: COLLABBLS, CHIO, US. ZHANG, STRIBBLS GT AL "Tetranselear literaturels, and Consumer Copper (II) Convenience of a Series of Novo Desdribe Perhiphthat zone) Lipsuing XEVO233349 retrieved from STN Database accession no 1995/875232 abstract & Inorganes Chemistey, vol.34, no 23, 1995, pages 5871- 5877				

Examiner		Date	
Signature		Considered	
*EXAMINER: In	itial if reference considered, whether or not citation is in conformance with MPEP 605	9. Draw line through c	itation if not in conformance and not

considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including aghatering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Trademark Office, P.O., Box 1469, Ackandriq V.A. 2331-1450. DO NOT SEND FEES OR COMMILETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for form 1449/PTO Application Number 10/599.143 INFORMATION DISCLOSURE [ Filing Date Apri 1, 2005 STATEMENT BY APPLICANT First Named Inventor Lain-Yen Hu Art Unit (Use as many sheets as necessary) Examiner Name Attorney Docket Number PC32134A Sheet 5 5 of

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		DATAMASS CAPLIS, COME CHEMICAL, ADSTRACTS SERVICE, COLUMBUS, (HID, U.S. KORAYASHI, NAGAGI ET AL.  "Opposibly serve Publisheyamines and beit results dictiones". ZVIEGASSISS Proteored from STE Database accessive on 1993.652129 shatract & JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 115, no. 23, 1993, pages 19794-19995	
		DATABASE CAPLUS, Online CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, KELLER, TEDDY M. ET AL. "Synthesis of phthalonintles by nitro displacement", XP002333851 ctrisved from STN Database accession no. 1981:442599 abstract & SYNTHEISK, no. 8, 1980, page 613	
		DATABASE CAPILIS, Online CHEMICAL ABSTRACTS SERVICE, COLLIBIUS, OHIO, US: DANN, OTTO ET Al- Syntheses of biscationi, trypanocidal 1-benzofuran compounds* XP00233852 retrieved from STN Database accession no. 1983;35380 abstract & LIEBIOS ANNALEN DER CHEMIE, no. 10, 1992, pages 1836	
		Co-pending commonly assigned, United States patent application. Serial Number: 11/415.935 filed May 2, 2006 now published as 2006-0232796AT2 on 11/09/2006.	
		Co-pending commonly assigned, United States patent application. Serial Number 11/175,097 filed July 5, 2006 now published as 2006-0009427A1 on 01/12/2006.	
		Co-pending ownmenly assigned. Unded States patent apphention. Serial Number 11:572,760 filed August 8, 2005	
		Co-pending commonly assigned, United States patent application. Serial Number 11/372,743 filed August 5, 2005.	
		Co-pending commonly assigned, United States putent application. Serial Number. 10:599,719 filed April 14, 2005.	
		Co-pending commonly assigned, United States patent application. Serial Number 60-706,413 5 filed August 5, 2005.	
		Co-pending commonly assigned. United States patent application. Serial Number 11/572,748. filed filed August 22, 2005	

Examiner	Date	1	
Signature	Considered		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique clation designation number (options). 2 Applicant is to place a check mark here if English language Translation is stateched.
This collection of information is required by 37 CFR 13.8. The information is required to obtain or retain a benefit by the public which is to file and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including glathering, preparing, and submitting the completed application from to the USPTO. Three will vary depending upon the Individual cases of the process of the Complete application from the USPTO. Three will vary depending upon the Individual cases of clarification of the USPTO. Three will be truthen, backed see also the Dotte Individual confidence of clarification of the USPTO. Three will be truthen, backed see also the Dotte Individual confidence of Complete Complete